MNBTD
ESPR

Moody National Bank Trust Division’s Esperion Therapeutics ESPR Stock Holding History

Moody National Bank Trust Division’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-94
Closed -$4K – 556
2019
Q1 		$4K Buy
+94
New +$4.22K ﹤0.01% 1046

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Moody National Bank Trust Division's ESPR Position: Q2 2019 in Review

Moody National Bank Trust Division sold out of Esperion Therapeutics (ESPR) in Q2 2019, closing a stake of 94 shares — an estimated $4K sold.

Moody National Bank Trust Division first reported a position in ESPR in Q1 2019 and held it in 1 quarter. The position peaked at $4K in Q1 2019. 167 funds tracked by Wall St. Rank hold ESPR as of Q2 2019.

  • Moody National Bank Trust Division reported no remaining Esperion Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Moody National Bank Trust Division sold 94 Esperion Therapeutics shares in Q2 2019, an estimated $4K.
  • Moody National Bank Trust Division first reported a position in Esperion Therapeutics in Q1 2019 and held it in 1 quarter.
  • Moody National Bank Trust Division's Esperion Therapeutics position peaked at $4K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2019.

Based on Moody National Bank Trust Division's 13F filing for Q2 2019, filed 22 Jul 2019.